tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Edward Nash, 143 are a BUY (90.51%), 13 are a HOLD (8.23%), 2 are a SELL (1.27%).
Analyst Edward Nash, currently employed at CANACCORD, carries an average stock price target met ratio of 45.18% that have a potential upside of 39.08% achieved within 225 days.
Edward Nash’s has documented 312 price targets and ratings displayed on 32 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on VRNA, Verona Pharma PLC ADR at 05-Nov-2024.
Analyst best performing recommendations are on BLUE (BLUEBIRD BIO).
The best stock recommendation documented was for BLUE (BLUEBIRD BIO) at 6/6/2017. The price target of $69.95 was fulfilled within 1 day with a profit of $6.38 (10.04%) receiving and performance score of 100.36.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$3
$2.89 (2627.27%)
$10
6 years 1 months 20 days ago
(13-Nov-2018)
0/5 (0%)
$1.07 (55.44%)
Hold
$3
$2.89 (2627.27%)
$19
6 years 1 months 21 days ago
(12-Nov-2018)
0/5 (0%)
$1 (50.00%)
Hold
6 years 1 months 24 days ago
(09-Nov-2018)
1/4 (25%)
$8.57 (47.07%)
31
Hold
$8
$7.89 (7172.73%)
$20
6 years 1 months 27 days ago
(06-Nov-2018)
1/5 (20%)
$4.75 (146.15%)
41
Buy
$22
$21.89 (19900.00%)
$28
6 years 10 months 19 days ago
(14-Feb-2018)
1/3 (33.33%)
$11.09 (101.65%)
22
Which stock is Edward Nash is most bullish on?
Which stock is Edward Nash is most reserved on?
What Year was the first public recommendation made by Edward Nash?
